Colorectal cancer 3

Common Name(s)

Colorectal cancer 3

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Colorectal cancer 3" returned 184 free, full-text research articles on human participants. First 3 results:

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
 

Author(s): Antonio Avallone, Maria Carmela Piccirillo, Luigi Aloj, Guglielmo Nasti, Paolo Delrio, Francesco Izzo, Elena Di Gennaro, Fabiana Tatangelo, Vincenza Granata, Ernesta Cavalcanti, Piera Maiolino, Francesco Bianco, Pasquale Aprea, Mario De Bellis, Biagio Pecori, Gerardo Rosati, Chiara Carlomagno, Alessandro Bertolini, Ciro Gallo, Carmela Romano, Alessandra Leone, Corradina Caracò, Elisabetta de Lutio di Castelguidone, Gennaro Daniele, Orlando Catalano, Gerardo Botti, Antonella Petrillo, Giovanni M Romano, Vincenzo R Iaffaioli, Secondo Lastoria, Francesco Perrone, Alfredo Budillon

Journal:

 

Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the second cause of cancer deaths in both sexes. Therefore, research in this field remains of great interest. The approval of bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal ...

Last Updated: 9 Feb 2016

Go To URL
The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression.
 

Author(s): Nelson Ho, Jodi Morrison, Andreza Silva, Brenda L Coomber

Journal:

 

Cancer cells heavily rely on the glycolytic pathway regardless of oxygen tension. Hexokinase II (HKII) catalyses the first irreversible step of glycolysis and is often overexpressed in cancer cells. 3-Bromopyruvate (3BP) has been shown to primarily target HKII, and is a promising ...

Last Updated: 20 Feb 2016

Go To URL
[Prognostic Factors of Stage 3 Colorectal Cancer in 433 Patients].
 

Author(s): De-cong Sun, Hui Mao, Zhi-kuan Wang, Yan Shi, Guang-hai Dai

Journal: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015 Oct;37(5):549-56.

 

To summarize the prognostic factors of stage 3 colorectal cancer.

Last Updated: 13 Nov 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Colorectal cancer 3" returned 3 free, full-text review articles on human participants. First 3 results:

New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
 

Author(s): Arvind Dasari, Wells A Messersmith

Journal: Clin. Cancer Res.. 2010 Aug;16(15):3811-8.

 

Initial experience with the epidermal growth factor receptor monoclonal antibodies (EGFR MoAb) in unselected patients with metastatic colorectal cancer (mCRC) showed that most of the treated patients did not derive therapeutic benefit. This outcome has driven the search for biomarkers ...

Last Updated: 30 Jul 2010

Go To URL
Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach.
 

Author(s): Anna R Gagliardi, Marko Simunovic, Bernard Langer, Hartley Stern, Adalsteinn D Brown

Journal: Can J Surg. 2005 Dec;48(6):441-52.

 

Little performance measurement has been undertaken in the area of oncology, particularly for surgery, which is a pivotal event in the continuum of cancer care. This work was conducted to develop indicators of quality for colorectal cancer surgery, using a 3-step modified Delphi approach.

Last Updated: 18 Jan 2006

Go To URL
Omega-3 fatty acids in colorectal cancer prevention.
 

Author(s): Bandaru S Reddy

Journal: Int. J. Cancer. 2004 Oct;112(1):1-7.

 

Last Updated: 12 Aug 2004

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
 

Status: Recruiting

Condition Summary: Colorectal Cancer; Colon Cancer; Rectal Cancer; Solid Tumor

 

Last Updated: 28 Sep 2016

Go to URL
Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
 

Status: Not yet recruiting

Condition Summary: Colorectal Cancer

 

Last Updated: 24 Oct 2016

Go to URL